Brookline Capital Markets Starts ProMIS Neurosciences (PMN) at Buy May 20, 2026 06:26AM
ProMIS Neurosciences, Inc. (PMN) Misses Q1 EPS by 105c May 12, 2026 08:45AM
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference Apr 13, 2026 07:30AM
ProMIS Neurosciences (PMN) files for 13.83M share offering by selling stockholders Mar 18, 2026 04:19PM
ProMIS publishes study on selective targeting of toxic proteins Dec 10, 2025 07:30AM


Nov 18, 2025 06:29AM ProMIS Neurosciences (PMN) PT Lowered to $5 at Guggenheim
Nov 12, 2025 07:09AM ProMIS Neurosciences, Inc. (PMN) Reports In-Line Q3 EPS
Oct 22, 2025 07:31AM ProMIS Neurosciences (PMN) Appoints Dr. Slanix Paul Alex to Board
Sep 4, 2025 04:33PM ProMIS Neurosciences (PMN) files for 28.23M share offering by selling stockholders
Aug 13, 2025 06:51PM ProMIS Neurosciences, Inc. (PMN) Misses Q2 EPS by 13c
Aug 13, 2025 04:38PM ProMIS Neurosciences (PMN) Files $50M Mixed Shelf
Jul 28, 2025 07:01AM ProMIS Neurosciences raises $12 million through warrant financing
Jul 22, 2025 08:53AM ProMIS neurosciences raises $0.8 million in registered direct offering
Jul 22, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on ProMIS Neurosciences (PMN)
Jul 21, 2025 08:04AM ProMIS Neurosciences receives FDA fast track status for Alzheimer's drug
May 13, 2025 06:33AM ProMIS Neurosciences, Inc. (PMN) Misses Q1 EPS by 6c
Mar 24, 2025 07:01AM ProMIS Neurosciences (PMN) Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at AD/PD
Mar 13, 2025 07:00AM ProMIS Neurosciences (PMN) Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases
Feb 25, 2025 07:01AM ProMIS Neurosciences (PMN) Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
Jan 13, 2025 10:40AM ProMIS Neurosciences (PMN) Issues Letter to Shareholders
Jan 10, 2025 07:03AM ProMIS Neurosciences (PMN) Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
Nov 14, 2024 05:20PM ProMIS Neurosciences, Inc. (PMN) Tops Q3 EPS by 7c
Oct 30, 2024 08:01AM ProMIS Neurosciences (PMN) Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
Sep 12, 2024 07:03AM ProMIS Neurosciences (PMN) to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cogn
Jul 26, 2024 08:35AM ProMIS Neurosciences (PMN) Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
Jul 26, 2024 08:34AM ProMIS Neurosciences (PMN) Announces Up to $122.7 Million Private Placement Financing